Hypera (OTCMKTS:HYPMY) Issues Quarterly Earnings Results

Hypera (OTCMKTS:HYPMY - Get Free Report) issued its earnings results on Thursday. The company reported $0.02 earnings per share (EPS) for the quarter, Zacks reports. Hypera had a net margin of 20.04% and a return on equity of 13.18%. The firm had revenue of $258.56 million during the quarter.

Hypera Stock Performance

Shares of HYPMY stock traded up $0.16 on Wednesday, hitting $3.51. The company had a trading volume of 424 shares, compared to its average volume of 8,591. Hypera has a twelve month low of $2.64 and a twelve month high of $6.83. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.68. The firm has a market cap of $2.22 billion, a P/E ratio of 8.78 and a beta of 0.99. The company has a 50-day moving average price of $3.29 and a 200-day moving average price of $3.70.

Hypera Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.